Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic to Help Solvay Pharma Reposition Failed Rxs

NEW YORK (GenomeWeb News) — Gene Logic today said it will help Solvay Pharmaceuticals identify alternative development paths for multiple undisclosed drug candidates.
 
All of these drug candidates were discontinued or de-prioritized in clinical trials for reasons other than safety.
 
Terms of the deal call for Gene Logic to pocket milestone and royalty payments similar to those paid for development-stage in-licensing deals, discounted for the fact that Solvay originally identified the compounds.
 
The deal also gives Gene Logic the option to receive an exclusive license to any candidate for which Gene Logic identifies a potential new therapeutic use that Solvay chooses not to develop. If Gene Logic elects to obtain such a license, Solvay would be entitled to success-based milestone and royalty payments.
 
Last week, Gene Logic said it would help Merck Serono, a division of German drug maker Merck, identify alternative development paths for “several” undisclosed drug candidates.

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.